



**Biolux Research Announces Appointment of President and CEO for Commercialization of its OsseoPulse™ Bone Regeneration System.**

**VANCOUVER, B.C., CANADA - April 4, 2008** - Biolux Research Ltd. announced today that it has appointed medical device industry veteran Kevin Strange as President and CEO. Mr. Strange's primary responsibilities will be to lead the commercialization of the unique OsseoPulse™ Bone Regeneration System for dentistry, including product launch into Canada, the US, and Europe, as well as executing work in Korea with our strategic partner DIO Implant, subsidiary of a publicly listed medical device manufacturer and distributor. Dr. Peter Brawn, Chairman and Founder of Biolux, will continue the key roles of clinical and scientific visionary and early product research and development.

Mr. Strange has extensive medical device experience through a range of companies and roles. Most recently, he was Director of Business Development with StarFish Medical, a private contract medical device development and manufacturing company which provides services for a great range of medical companies and clinical markets. Prior to that, he spent eight years in a variety of operational and marketing roles with VSM MedTech Ltd in Vancouver, BC, a public medical device company that developed and marketed vital signs monitoring equipment and cortical functional brain imaging systems. During Mr. Strange's time at VSM, the company grew from 5 to 150 employees and from pre-revenue to approximately \$15M revenue. Prior to VSM, he was involved in a spin-off company from Simon Fraser University that developed implantable neural recording and stimulation devices for use in restoring function following paralysis.

"I am thrilled to be joining Biolux at this very exciting point, and look forward to applying my experience and energy to the challenges ahead," states Mr. Strange. "The clinical results to date are very promising, and indicate a significant clinical effect in implantology and bone regeneration, and the advisory team gives me confidence that the OsseoPulse™ will be successful in the market."

"We are excited at being able to attract Kevin and his expertise to our venture, and we feel very confident that 2008 is going to be a breakthrough year for Biolux," says Dr. Brawn. In addition, the company announces that the corporate head office will move in April 2008 to a location that can better accommodate anticipated developments.

**About Biolux Research**

Biolux Research Ltd. is a world leader in the development of light activated bone regeneration systems for dentistry. Biolux focuses on product development, clinical and basic research and is well positioned to release its OsseoPulse™ system to the marketplace in 2008. Its proprietary, patent pending OsseoPulse™ Bone Regeneration System is premised on a vision to transform the practice of implantology and oral surgery in dentistry by accelerating implant integration and bone regeneration in a safe, effective and non-invasive approach.

**For More Information:**

Kevin Strange  
President & CEO  
Biolux Research Ltd.  
+1 (250) 686-1120  
[k.strange@bioluxresearch.com](mailto:k.strange@bioluxresearch.com)